MayoComplete Lung Rearrangements, Rapid Test, Tumor
Use
This test is useful for identifying lung tumors that may respond to targeted therapies by simultaneously assessing multiple genes involved in rearrangements that result in fusion transcripts. It is significant for diagnosing and managing patients with lung cancer, looking specifically at gene fusions involving ALK, ROS1, RET, MET exon 14 skipping, and expression imbalance for ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3 genes.
Special Instructions
A pathology report containing the patient's name, block number, tissue collection date, and source of the tissue must accompany the specimen for testing to be performed. A slide review will always be performed at an additional charge.
Limitations
This test cannot differentiate between somatic and germline alterations. A negative result does not rule out the presence of a rearrangement (fusion) that may be below the limits of detection of this assay. Only gene fusions (rearrangements) and expression imbalance involving ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3 genes will be detected. This test does not detect point mutations, deletion-insertion mutations, large single or multiexon deletions or duplications, or genomic copy number variants in any of the genes tested. Rare alterations could lead to false-negative or false-positive results.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 73977-1
- 82939-0
- 69047-9
- 48767-8
- 31208-2
- 80398-1
- 85069-3
- 62364-5
- 18771-6
Result Turnaround Time
4-8 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin-fixed, paraffin-embedded tissue block or slide
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue, or slides with hematoxylin and eosin stain and specified number of unstained slides.